Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Dec;16(6):738–740. doi: 10.1111/j.1365-2125.1983.tb02254.x

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

O Haagen Nielsen, S Bondesen
PMCID: PMC1428338  PMID: 6661362

Abstract

The human pharmacokinetics of 5-aminosalicylic acid (5-ASA), the active moiety of salazosulphapyridine (SASP), is only known from studies in which rapid absorption has been deliberately avoided. The present investigation demonstrates that pure 5-ASA is absorbed extremely quickly when given as an instillation in the proximal part of the small bowel, and acetylation follows immediately. The metabolite is excreted very rapidly by the liver in small amounts, while the major part is eliminated renally.

Full text

PDF
738

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Truelove S. C. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis. Gut. 1980 Aug;21(8):706–710. doi: 10.1136/gut.21.8.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Azadkhan A. K., Truelove S. C., Aronson J. K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982 Apr;13(4):523–528. doi: 10.1111/j.1365-2125.1982.tb01415.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Calder I. C., Williams P. J., Woods R. A., Funder C. C., Green C. R., Ham K. N., Tange J. D. Nephrotoxicity and molecular structure. Xenobiotica. 1975 May;5(5):303–307. doi: 10.3109/00498257509052064. [DOI] [PubMed] [Google Scholar]
  5. Das K. M., Chowdhury J. R., Zapp B., Fara J. W. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology. 1979 Aug;77(2):280–284. [PubMed] [Google Scholar]
  6. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fischer C., Maier K., Klotz U. Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. Br J Clin Pharmacol. 1983 Feb;15(2):273–274. doi: 10.1111/j.1365-2125.1983.tb01499.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hansen S. H. Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr. 1981 Dec 11;226(2):504–509. doi: 10.1016/s0378-4347(00)86089-2. [DOI] [PubMed] [Google Scholar]
  9. Morgan T., Adam W., Gillies A., Wilson M., Morgan G., Carney S. Hypertension treated by salt restriction. Lancet. 1978 Feb 4;1(8058):227–230. doi: 10.1016/s0140-6736(78)90479-8. [DOI] [PubMed] [Google Scholar]
  10. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  11. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  12. Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
  13. Willoughby C. P., Aronson J. K., Agback H., Bodin N. O., Truelove S. C. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut. 1982 Dec;23(12):1081–1087. doi: 10.1136/gut.23.12.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Willoughby C. P., Piris J., Truelove S. C. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol. 1980;15(6):715–719. doi: 10.3109/00365528009181520. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES